Show simple item record

dc.contributor.authorBegley, C Glenn
dc.contributor.authorAshton, Mark
dc.contributor.authorBaell, Jonathan
dc.contributor.authorBettess, Michael
dc.contributor.authorBrown, Michael P
dc.contributor.authorCarter, Brett
dc.contributor.authorCharman, William N
dc.contributor.authorDavis, Christopher
dc.contributor.authorFisher, Simon
dc.contributor.authorFrazer, Ian
dc.contributor.authorGautam, Anand
dc.contributor.authorJennings, Michael P
dc.contributor.authorKearney, Philip
dc.contributor.authorKeeffe, Eloise
dc.contributor.authoret al.
dc.date.accessioned2021-10-15T05:15:08Z
dc.date.available2021-10-15T05:15:08Z
dc.date.issued2021
dc.identifier.issn1946-6234en_US
dc.identifier.doi10.1126/scitranslmed.abd5524en_US
dc.identifier.urihttp://hdl.handle.net/10072/409102
dc.description.abstractDrug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a new indication. This may explain the inability of drug repurposing to fulfill its promise. Important aspects, often overlooked, include financial and intellectual property considerations, the clinical and regulatory path, and clinical equipoise, which provides ethical justification for randomized controlled trials. The goal of drug repurposing is to obtain a new regulator-approved label for an existing drug, and so, the trajectory for drug repurposing and traditional drug development is similar. Here, we discuss factors critical for a successful repurposed medicine to help academic investigators better identify drug repurposing opportunities.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherThe American Association for the Advancement of Science (AAAS)en_US
dc.relation.ispartofissue612en_US
dc.relation.ispartofjournalScience Translational Medicineen_US
dc.relation.ispartofvolume13en_US
dc.subject.fieldofresearchPharmacology and pharmaceutical sciencesen_US
dc.subject.fieldofresearchClinical sciencesen_US
dc.subject.fieldofresearchcode3214en_US
dc.subject.fieldofresearchcode3202en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsCell Biologyen_US
dc.subject.keywordsMedicine, Research & Experimentalen_US
dc.subject.keywordsResearch & Experimental Medicineen_US
dc.titleDrug repurposing: Misconceptions, challenges, and opportunities for academic researchersen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationBegley, CG; Ashton, M; Baell, J; Bettess, M; Brown, MP; Carter, B; Charman, WN; Davis, C; Fisher, S; Frazer, I; Gautam, A; Jennings, MP; Kearney, P; Keeffe, E; et al., Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers, Science Translational Medicine, 2021, 13 (612)en_US
dc.date.updated2021-10-12T03:58:17Z
gro.hasfulltextNo Full Text
gro.griffith.authorJennings, Michael P.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record